University of Montana vaccine research expands, The UM Center for Translational Medicinesoon to conduct clinical trials
UM’s Vaccine Discovery and Development Team at the Center for Translational Medicine has been researching and developing vaccines for opioid addiction, COVID-19, tuberculosis, influenza, pertussis, pseudomonas, lyme disease, E. coli and HIV.
The opioid, COVID-19 and tuberculosis programs have been gaining momentum recently, according to Jay Evans, director of the Center for Translational Medicine at UM.
“Finding the right students and staff who are interested in working on vaccines has been great,” Evans said. “UM provides us with great students and a great environment.”
The hope for the research in Montana is that it will lead to recommendations on how to manage land in ways that don’t increase the prevalence of the disease.
Montana State University again designated R1 – among top U.S. research universities in Carnegie classification
Only 146 institutions in the nation received R1 classifications, and among them, MSU and Utah State University are the only two that also have an enrollment profile of “very high undergraduate.”
“UM reaching R1 status is a great testament to the quality of our faculty, staff and students,” said Scott Whittenburg, UM vice president for research and creative scholarship. “Being one of the top research universities in the country also will help us recruit new students and faculty to campus.”
Sorry, we couldn't find any posts. Please try a different search.